Feb 10, 2021
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial
Jan 18, 2021
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Dec 17, 2020
Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer
Aug 06, 2020
Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma
May 04, 2020
Tessa Therapeutics Announces New Executive Leadership
Feb 27, 2020
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma
Dec 19, 2019
Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020
Jun 12, 2019
Tessa Therapeutics and China-Singapore Guangzhou Knowledge City Form Landmark US$120 Million Joint Venture in China to Develop Innovative Cell Therapies for Cancer
Apr 30, 2019
Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy
Apr 15, 2019
Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer
Feb 28, 2019
Tessa Therapeutics Names Biopharma Veteran Jeffrey H. Buchalter to Board of Directors
Dec 20, 2018
Distinguished Breast Cancer Expert, Dr. George W. Sledge, Jr., M.D., to join the Board of Tessa Therapeutics
Sep 20, 2018
St. Jude Children's Research Hospital and Tessa Therapeutics Announce Strategic Collaboration
Sep 19, 2018
T-Cell Immunotherapy Market, 2030 - Primary Growth Drivers and Estimations of the Future Size of the Market
Apr 11, 2018
Tessa Therapeutics announces new Board Member and increase of recent funding round
Feb 05, 2018
Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial
Dec 19, 2017
Tessa Therapeutics Closes USD 80 Million Financing Round Led by Temasek
Dec 11, 2017
Tessa Therapeutics Appoints Mr. Desmond Lim as Chief Financial Officer
Jun 19, 2017
Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Strategic Alliance Agreement